MabTics
MabTics
is a spin-off company established from Korea Researech Institute of Bioscience and Biotechnogy (KRIBB) and pursues to make better therapeutics, especially by developing mono- and bi-specific antibodies for treating vascular diseases and cancers.
Antibody-based vessel normalization
Bispecific antibody for wAMD
Anti-thromboinflammatory antibody
Tumor-targeting antibodies
A proprietary high-diverse antibody library
EAGLES platform
MabTics
History
| 2026.05 | Bispecific antibody MT-103 for ophthalmic diseases out-licensed |
|---|---|
| 2024.07 | Execution of joint pipeline development contract with Curacle |
| 2024.06 | SI funding (1.3 billion KRW) |
| 2024.04 | MT-103 for ophthalmic diseases selected for KDDF project |
| 2023.07 | SI funding (1 billion KRW) |
| 2023.06 | Signs MOU with Curacle for development of bispecific antibody for treating wAMD |
| 2023.04 | MT-101 for renal diseases selected for KDDF(Korea Drug Development Fund) project |
| 2023.01 | R&D Center affiliated |
| 2022.12 | Seed funding (1.1 billion) |
| 2022.10 | Certificated as venture business |
| 2022.07 | Establishment of MabTics |